Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
IONS Ionis Pharmaceuticals, Inc. daily Stock Chart
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E40.42 EPS (ttm)1.95 Insider Own0.20% Shs Outstand141.20M Perf Week0.46%
Market Cap11.14B Forward P/E117.24 EPS next Y0.67 Insider Trans-51.62% Shs Float125.75M Perf Month37.43%
Income273.70M PEG1.01 EPS next Q0.70 Inst Own85.90% Short Float9.92% Perf Quarter55.13%
Sales599.70M P/S18.58 EPS this Y139.20% Inst Trans0.09% Short Ratio12.48 Perf Half Y57.86%
Book/sh7.96 P/B9.91 EPS next Y278.09% ROA12.90% Target Price65.46 Perf Year54.34%
Cash/sh14.76 P/C5.35 EPS next 5Y40.00% ROE39.70% 52W Range39.07 - 81.03 Perf YTD45.95%
Dividend- P/FCF18.90 EPS past 5Y41.70% ROI13.60% 52W High-2.63% Beta2.40
Dividend %- Quick Ratio7.80 Sales past 5Y32.40% Gross Margin43.30% 52W Low101.95% ATR2.19
Employees737 Current Ratio7.90 Sales Q/Q14.50% Oper. Margin-10.20% RSI (14)74.55 Volatility2.35% 3.55%
OptionableYes Debt/Eq0.62 EPS Q/Q176.00% Profit Margin45.60% Rel Volume0.79 Prev Close80.50
ShortableYes LT Debt/Eq0.60 EarningsFeb 27 BMO Payout0.00% Avg Volume999.04K Price78.90
Recom2.90 SMA209.12% SMA5023.91% SMA20050.62% Volume790,899 Change-1.99%
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Dec-27-16Reiterated Laidlaw Buy $59 → $65
Nov-10-16Resumed Leerink Partners Mkt Perform
Aug-10-16Reiterated Piper Jaffray Overweight $36 → $46
Aug-03-16Initiated Morgan Stanley Equal-Weight $37
Aug-02-16Reiterated Needham Buy $55 → $64
Aug-02-16Reiterated Barclays Equal Weight $26 → $41
May-27-16Reiterated Needham Buy $88 → $55
Mar-15-19 04:05PM  Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19) GlobeNewswire
Mar-08-19 04:39PM  IBD Stock Of The Day Obliterates Earnings Views And Eyes New Buy Point Investor's Business Daily
12:27PM  6 of the Most Expensive Stocks That Could Go On Sale InvestorPlace
Mar-07-19 07:05AM  Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Mar-05-19 12:22AM  Edited Transcript of IONS earnings conference call or presentation 27-Feb-19 4:30pm GMT Thomson Reuters StreetEvents
Mar-04-19 03:46PM  Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs Motley Fool
12:00AM  Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-01-19 03:48PM  Ionis Pharmaceuticals Inc (IONS) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
08:44AM  EU committee approves Akcea-Ionis drug for rare genetic disease Reuters
07:45AM  Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen) GlobeNewswire
Feb-27-19 07:52PM  Ionis Pharmaceuticals (IONS) Q4 2018 Earnings Conference Call Transcript Motley Fool +15.12%
02:35PM  Here's Why Ionis Pharmaceuticals Jumped Higher Today Motley Fool
07:00AM  Ionis Exceeds 2018 Financial Guidance PR Newswire
Feb-25-19 10:40AM  Novartis aims to pump up cardio business with Ionis deal Reuters
10:27AM  Novartis In-Licenses Rights to Heart Candidate From Ionis Zacks
Feb-20-19 10:31AM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-14-19 12:01PM  Is Moderna a Buy? Motley Fool
Feb-13-19 07:05AM  Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast PR Newswire
Feb-12-19 02:46PM  Is Ionis Pharmaceuticals, Inc.s (NASDAQ:IONS) CEO Pay Fair? Simply Wall St.
Jan-30-19 04:49PM  Biogen Looks to 2020 Motley Fool
11:18AM  Ionis Wins Price Target Hike On Partner Biogen's Guidance Benzinga
Jan-28-19 09:30AM  Has Ionis Pharmaceuticals (IONS) Outpaced Other Medical Stocks This Year? Zacks
07:00AM  First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease PR Newswire
Jan-24-19 04:18PM  Is This 'Perennial' Innovator Making A Comeback Among Biotech Stocks? Investor's Business Daily
10:44AM  Ironwood Commences Phase I Study on IW-6463 for CNS Disorders Zacks
Jan-16-19 06:57AM  4 Defensive Stocks to Buy Amid Shutdown and Brexit Zacks
Jan-15-19 08:00AM  Pfizer Gets FDA's Priority Review for Rare Disease Candidate Zacks
Jan-14-19 04:23PM  This Biotech Stock Plunged On Its Looming Rivalry With Pfizer Investor's Business Daily
Jan-12-19 06:00PM  3 Top Biotech Stocks to Buy in January Motley Fool
Jan-02-19 03:48PM  Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018 Investor's Business Daily
07:05AM  Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference PR Newswire
06:00AM  Top Picks 2019- Ionis Pharmaceuticals IONS MoneyShow
Dec-31-18 07:51AM  4 of the Fastest Growing Biotech Stocks in 2019 Motley Fool +5.26%
Dec-21-18 04:26PM  Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug Investor's Business Daily
Dec-20-18 06:39PM  Ionis Pharmaceuticals outlines CEO succession plan MarketWatch
05:41PM  Ionis Announces Plans for Management Transitions in 2020 PR Newswire
07:20AM  New Research: Key Drivers of Growth for Baxter International, Sempra Energy, Nielsen Holdings Plc, ARRIS International plc, Ionis Pharmaceuticals, and KB Home Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-14-18 12:47AM  Should You Buy Ionis Pharmaceuticals, Inc. (IONS)? Insider Monkey
Dec-13-18 09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks
Dec-12-18 10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
Dec-11-18 11:19AM  Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Expensive For A Reason? A Look At The Intrinsic Value Simply Wall St.
Dec-06-18 07:30AM  Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data GlobeNewswire
Nov-29-18 05:30PM  Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis Investor's Business Daily
07:30AM  International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product GlobeNewswire
Nov-27-18 07:00AM  First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting PR Newswire
Nov-19-18 05:00AM  Edited Transcript of IONS earnings conference call or presentation 6-Nov-18 4:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 09:15AM  Stocks Not in a Bouncy Mood Yet Zacks
Nov-13-18 07:07AM  Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference PR Newswire
Nov-12-18 03:16PM  5 Pharma Stocks to Stay Away From InvestorPlace
12:50PM  Ionis Pharmaceuticals Collects Royalties -- and Spends It All Motley Fool
06:55AM  Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions GlobeNewswire
Nov-09-18 07:07AM  Ionis Pharmaceuticals to Host Investor Day PR Newswire
Nov-08-18 09:00AM  Recent Analysis Shows Automatic Data Processing, GTx, Ionis Pharmaceuticals, TriNet Group, Ternium S.A, and UNIVERSAL INSURANCE HOLDINGS INC Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:00AM  Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions GlobeNewswire
Nov-07-18 07:00AM  Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Nov-06-18 05:48PM  Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript Motley Fool
08:30AM  Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:27AM  Ionis Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:00AM  Ionis Reports Third Quarter 2018 Financial Results PR Newswire
Oct-31-18 07:00AM  Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting PR Newswire
Oct-24-18 08:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and Ionis Pharmaceuticals ACCESSWIRE -5.79%
07:00AM  Ionis Pharmaceuticals to Hold Third Quarter 2018 Financial Results Webcast PR Newswire
Oct-23-18 07:00AM  Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science PR Newswire
Oct-22-18 08:45AM  Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology PR Newswire
Oct-17-18 10:00AM  Billionaire Tech Titans Award Millions to Make Scientists Stars Bloomberg
08:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Gogo, Jagged Peak Energy, Everbridge, Roku, Corium International, and Ionis Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Oct-11-18 07:00AM  Here's Why Ionis Pharmaceuticals Rose 12.9% in September Motley Fool
Oct-10-18 10:12AM  [$$] Ionis, Roche Reach New Collaboration Agreement The Wall Street Journal
09:27AM  Ionis's stock surges after Roche collaboration, which could be worth up to $759 million MarketWatch
09:07AM  Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases PR Newswire
Oct-08-18 07:00AM  Akcea Announces Changes to Board of Directors GlobeNewswire -7.65%
Oct-05-18 07:11PM  Cambridge's Akcea rebounds with FDA approval of first drug American City Business Journals
06:17PM  Akcea Therapeutics genetic disease treatment gets FDA approval Reuters
05:33PM  Akcea Announces Its Access and Distribution Strategy for TEGSEDI (inotersen) GlobeNewswire
05:32PM  Akcea and Ionis Receive FDA Approval of TEGSEDI (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults GlobeNewswire
Sep-27-18 09:32AM  When Will Ionis Pharmaceuticals Inc (NASDAQ:IONS) Become Profitable? Simply Wall St.
Sep-24-18 04:06PM  Ionis Announces the Appointment of Two New Board Members PR Newswire
Aug-29-18 09:23AM  Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover? Motley Fool
07:35AM  3 Big Stock Charts for Wednesday: PG&E, PepsiCo and Hewlett Packard Enterprise InvestorPlace
07:09AM  Ionis stock drops 13% as FDA fails to approve key drug MarketWatch
07:00AM  Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Aug-28-18 04:34PM  Why Canopy Growth, Mitek Systems, and Ionis Pharmaceuticals Slumped Today Motley Fool -15.88%
12:51PM  Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today Motley Fool
10:24AM  Akcea Plunges as Analysts Fear Wider Fallout From Drug Setback Bloomberg
08:45AM  Ionis Pharmaceuticals (IONS) Looks Good: Stock Adds 7.8% in Session Zacks
08:13AM  The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic Benzinga
Aug-27-18 05:47PM  After-hours buzz: AMD, AKCA, IONS & more CNBC +7.83%
05:30PM  FDA rejects rare disease drug developed by Cambridge's Akcea American City Business Journals
05:07PM  Akcea, Ionis shares drop after disappointing FDA decision MarketWatch
05:01PM  What Happened in the Stock Market Today Motley Fool
04:39PM  U.S. FDA declines to approve Akcea/Ionis genetic disease drug Reuters
04:30PM  Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA GlobeNewswire
02:59PM  Pfizer Slips Despite Mostly Positive Tafamidis Data; 4 Pharma Stocks Make Sympathy Moves Benzinga
01:07PM  Here's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped Today Motley Fool
08:38AM  Pfizer rare-disease drug results lift its shares and those of rival MarketWatch
Aug-23-18 10:02AM  Recent Analysis Shows Fitbit, Southwestern Energy, DAQO New Energy, ANGI Homeservices, Inc., Ionis Pharmaceuticals, and Cronos Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-22-18 03:52PM  Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO? Motley Fool
Aug-20-18 11:59PM  Edited Transcript of IONS earnings conference call or presentation 7-Aug-18 3:30pm GMT Thomson Reuters StreetEvents
08:00AM  3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro Motley Fool
Aug-17-18 10:02PM  Heres Why Alnylams Shares Are Tumbling Motley Fool
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WENDER JOSEPH HDirectorMar 19Sale79.6310,000796,25858,916Mar 20 06:05 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Option Exercise61.5728,8001,773,21648,473Mar 20 06:15 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Sale78.7928,8002,269,18719,673Mar 20 06:15 PM
PARSHALL B LYNNEDirectorMar 12Option Exercise39.878,334332,27761,011Mar 14 06:24 PM
PARSHALL B LYNNEDirectorMar 12Sale75.008,334625,05052,677Mar 14 06:24 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Option Exercise45.1126,8001,208,95233,773Mar 01 05:40 PM
PARSHALL B LYNNEDirectorFeb 27Option Exercise39.878,333332,23761,010Mar 01 05:56 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Sale68.0126,8001,822,58019,673Mar 01 05:40 PM
PARSHALL B LYNNEDirectorFeb 27Sale70.008,333583,31052,677Mar 01 05:56 PM
CROOKE STANLEY TChairman and CEOFeb 26Option Exercise39.8737,0001,475,190106,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 26Sale61.5437,0002,276,79969,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 25Option Exercise39.8740,0001,594,800109,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 25Sale60.0740,0002,402,70069,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 13Option Exercise33.126,904228,66610,832Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Option Exercise39.8740,0001,594,800109,634Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Sale60.006,904414,2405,532Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Sale60.1040,0002,404,02869,634Feb 14 05:57 PM
Geary Richard SSVP, DevelopmentFeb 13Sale60.0099959,94021,442Feb 14 05:51 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 12Option Exercise39.8727510,96419,948Feb 14 06:01 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 12Sale59.5027516,36319,673Feb 14 06:01 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 05Option Exercise39.8715,600621,97235,273Feb 05 06:05 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 05Sale59.5015,600928,20019,673Feb 05 06:05 PM
BENNETT C FRANKSVP, Antisense ResearchFeb 01Option Exercise14.699,013132,40133,541Feb 05 05:59 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 01Option Exercise39.874,000159,48023,673Feb 05 06:05 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 01Sale58.294,000233,16019,673Feb 05 06:05 PM
BENNETT C FRANKSVP, Antisense ResearchFeb 01Sale58.299,013525,36824,528Feb 05 05:59 PM
BENNETT C FRANKSVP, Antisense ResearchJan 15Option Exercise0.007,822027,218Jan 17 07:39 PM
Geary Richard SSVP, DevelopmentJan 15Option Exercise0.008,085024,942Jan 17 07:36 PM
HOUGEN ELIZABETH LSVP Finance & CFOJan 15Option Exercise0.007,891022,665Jan 17 07:35 PM
Monia Brett PChief Operating OfficerJan 15Option Exercise0.0010,006025,847Jan 17 07:34 PM
CROOKE STANLEY TChairman and CEOJan 15Option Exercise0.002,34606,474Jan 17 07:27 PM
CROOKE STANLEY TChairman and CEOJan 15Option Exercise0.0030,587082,320Jan 17 07:27 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 15Option Exercise0.007,823022,341Jan 17 07:24 PM
PARSHALL B LYNNEDirectorJan 15Option Exercise0.0020,656058,836Jan 17 07:19 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 03Option Exercise37.234,400163,80818,584Jan 03 07:50 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 03Sale54.804,400241,12014,584Jan 03 07:50 PM
Monia Brett PChief Operating OfficerJan 02Sale53.5021411,44915,837Jan 03 07:42 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 19Option Exercise7.252,06314,95716,837Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 19Sale52.052,063107,37914,774Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 18Option Exercise7.252,00014,50016,774Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 18Sale52.002,000104,00014,774Dec 20 05:55 PM
Monia Brett PChief Operating OfficerNov 23Option Exercise14.6934,000499,46049,841Nov 26 08:01 PM
Monia Brett PChief Operating OfficerNov 23Sale55.0034,0001,870,05815,841Nov 26 08:01 PM
BENNETT C FRANKSVP, Antisense ResearchNov 01Option Exercise14.6912,500183,62531,896Nov 01 07:34 PM
BENNETT C FRANKSVP, Antisense ResearchNov 01Sale49.5412,500619,24519,396Nov 01 07:34 PM
Monia Brett PChief Operating OfficerAug 27Option Exercise7.2316,493119,27424,834Aug 29 04:49 PM
Monia Brett PChief Operating OfficerAug 27Sale54.0016,493890,62215,841Aug 29 04:49 PM
BENNETT C FRANKSVP, Antisense ResearchAug 08Option Exercise14.6812,500183,52831,883Aug 09 06:34 PM
BENNETT C FRANKSVP, Antisense ResearchAug 08Sale45.0012,500562,50019,396Aug 09 06:34 PM
Monia Brett PChief Operating OfficerJul 24Sale47.031567,33715,841Jul 25 07:19 PM
WENDER JOSEPH HDirectorJul 17Option Exercise9.2630,000277,80068,916Jul 19 06:45 PM
KLEIN JOSEPH IIIDirectorJul 03Option Exercise0.00667012,606Jul 03 03:07 PM
BERTHELSEN SPENCER RDirectorJul 03Option Exercise0.00667094,094Jul 03 03:08 PM
WENDER JOSEPH HDirectorJul 03Option Exercise0.00667038,916Jul 03 03:10 PM
Castleman BreauxDirectorJul 03Option Exercise0.00667012,294Jul 03 03:13 PM
LOSCALZO JOSEPHDirectorJul 03Option Exercise0.00667010,419Jul 03 03:20 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.002,00009,752Jul 03 03:20 PM
Castleman BreauxDirectorJul 01Option Exercise0.002,000011,627Jul 03 03:13 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.002,000038,249Jul 03 03:10 PM
BERTHELSEN SPENCER RDirectorJul 01Option Exercise0.002,000093,427Jul 03 03:08 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.002,000011,939Jul 03 03:07 PM
BERTHELSEN SPENCER RDirectorJun 25Option Exercise13.8815,000208,200100,727Jun 25 08:28 PM
BERTHELSEN SPENCER RDirectorJun 25Sale42.3015,000634,54291,427Jun 25 08:28 PM
MUTO FREDERICK TDirectorMay 31Option Exercise13.8815,000208,20022,127May 31 08:02 PM
MUTO FREDERICK TDirectorMay 31Sale46.4515,000696,7507,127May 31 08:02 PM
WENDER JOSEPH HDirectorMay 11Option Exercise13.8815,000208,20044,839May 11 09:00 PM
BENNETT C FRANKSVP, Antisense ResearchMay 11Option Exercise7.2512,50090,62531,614May 11 09:06 PM
WENDER JOSEPH HDirectorMay 11Sale45.3115,000679,61436,249May 11 09:00 PM
BENNETT C FRANKSVP, Antisense ResearchMay 11Sale45.0012,500562,50019,114May 11 09:06 PM
CROOKE STANLEY TChairman and CEOApr 17Option Exercise10.824,00043,2806,128Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Option Exercise14.699,962146,34256,714Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Sale44.404,000177,6004,128Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Sale44.409,962442,31351,733Apr 19 05:22 PM
KLEIN JOSEPH IIIDirectorMar 29Option Exercise24.422,00048,84011,939Mar 30 03:51 PM
KLEIN JOSEPH IIIDirectorMar 29Sale46.152,00092,3009,939Mar 30 03:51 PM
open in yahoo | open in reuters | open in google